GleamWall
中文EN

IDXX IDEXX LABORATORIES INC /DE

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 874716 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.9%
TTM net income YoY15.1%
TTM EPS YoY17.7%
Revenue 3-yr CAGR9.1%
Net income 3-yr CAGR12.8%

Margins

Gross margin62.7%
Operating margin32.3%
Net margin25.4%
FCF margin28.0%
EBITDA margin35.7%

Returns

ROE68.9%
ROA33.3%
ROIC (approx.)61.4%
Asset turnover1.31x

Leverage & solvency

Liabilities / assets49.6%
Debt / equity0.20x
Current ratio1.19x
Interest coverage43.54x

Cash quality & payout

Operating cash flow / net income1.20x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.21B$1.22B$1.14B$1.09B$1.11B$1.11B$998.43M$954.29M
Cost of revenue$449.94M$437.50M$418.08M$432.46M$421.88M$414.73M$375.05M$383.63M
Gross profit$764.30M$779.09M$722.74M$658.11M$683.35M$694.73M$623.38M$570.66M
R&D expense$68.82M$65.43M$65.79M$66.83M$63.41M$61.90M$59.06M$57.73M
SG&A expense$123.28M$116.81M$119.11M$108.62M$105.94M$98.68M$91.56M$101.14M
Operating income$402.35M$425.57M$362.59M$315.61M$354.85M$373.05M$316.53M$261.69M
Interest expense$7.46M$10.18M$7.74M$9.21M$10.65M$11.32M$7.67M$7.50M
Pretax income$399.32M$417.22M$355.44M$306.98M$344.77M$362.35M$310.08M$256.39M
Income tax$82.18M$78.81M$77.00M$58.79M$70.16M$68.36M$67.41M$40.24M
Net income$317.14M$338.41M$278.45M$248.19M$274.61M$293.99M$242.68M$216.15M
EBITDA$442.91M$466.62M$400.27M$354.33M$391.47M$408.82M$350.60M$295.39M
EPS (basic)4.024.293.50—3.433.662.98—
EPS (diluted)4.014.273.47—3.403.632.96—
Weighted avg. shares (diluted)79.05M79.31M80.16M—80.67M80.99M81.92M—
Banking
Provision for credit losses$1.57M$2.33M$3.94M$2.45M$1.62M$1.47M$2.89M$1.79M
Balance sheet
Cash & equivalents$197.54M$196.93M$200.53M$180.07M$208.17M$164.59M$163.97M$288.27M
Receivables$615.80M$627.08M$603.54M$552.38M$566.88M$560.56M$527.46M$473.57M
Inventory$390.87M$391.58M$382.40M$377.76M$391.56M$392.58M$395.99M$381.88M
Current assets$1.50B$1.51B$1.45B$1.41B$1.48B$1.36B$1.32B$1.40B
PP&E, net$732.13M$733.24M$740.38M$747.38M$739.44M$739.68M$717.62M$713.12M
Goodwill$640.51M$410.95M$412.10M$414.00M$413.65M$414.49M$407.49M$405.10M
Intangibles$117.77M$98.17M$104.75M$109.84M$114.79M$103.73M$107.41M$111.68M
Total assets$3.71B$3.44B$3.39B$3.35B$3.39B$3.33B$3.21B$3.29B
Current liabilities$1.26B$1.29B$1.30B$1.15B$1.25B$1.22B$1.14B$1.07B
Short-term debt$75.00M$150.00M$150.00M$75.00M$150.00M$74.99M$170.93M$167.79M
Long-term debt$299.88M$299.87M$299.85M$374.84M$374.82M$449.81M$449.80M$449.79M
Total debt$374.88M$449.86M$449.85M$449.84M$524.82M$524.81M$620.73M$617.57M
Total liabilities$1.84B$1.83B$1.83B$1.75B$1.83B$1.87B$1.77B$1.70B
Shareholders' equity$1.87B$1.61B$1.56B$1.61B$1.56B$1.46B$1.45B$1.60B
Net debt$177.34M$252.93M$249.32M$269.77M$316.66M$360.21M$456.76M$329.31M
Shares outstanding78.79M78.87M79.24M79.71M80.00M80.15M80.74M81.60M
Cash flow statement
Operating cash flow$449.72M$347.16M$266.25M$355.76M$402.34M$185.74M$237.96M$262.02M
Capital expenditure$28.93M$24.65M$31.98M$29.43M$31.11M$34.10M$30.03M$29.25M
Free cash flow$420.79M$322.52M$234.26M$326.33M$371.23M$151.64M$207.94M$232.77M
Investing cash flow-$248.10M-$25.50M-$33.54M-$28.13M-$44.87M-$33.63M-$29.61M-$39.84M
Financing cash flow-$200.85M-$325.19M-$211.43M-$355.70M-$313.31M-$165.63M-$330.32M-$232.78M
Depreciation & amortization$40.56M$41.05M$37.68M$38.72M$36.63M$35.77M$34.06M$33.71M
Stock-based compensation$16.20M$16.10M$16.34M$16.11M$14.40M$14.90M$14.62M$14.26M
Share buybacks$112.17M$346.80M$351.04M$237.77M$240.19M$338.11M$400.89M$245.99M

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.